Abstract 5385: Anticancer effects of a novel histone deacetylase inhibitor, SNUCH-1, in glioblastoma

Abstract

Abstract Histone deacetylase inhibitors (HDACi) have been evaluated as promising anticancer drugs against glioblastoma cells. However, there are still lack of animal experiments and new HDAC inhibitors for clinical trials. In this study, we demonstrated the therapeutic efficacy of novel pan-HDACi, SNUCH-1, comparing with other traditional pan-HDACi such as trichostatin A (TSA) and vorinostat (SAHA) in vitro and vivo. We performed cell viability, proliferation, cell cycle, apoptosis, HDAC enzyme activity and western blot assay using the three glioblastoma cell lines and two primary cultured cells. Furthermore, we examined the effects of SNUCH-1 by intracisternal administration on the orthotopic human xenograft glioblastoma mice model. We showed that SNUCH-1 decreased cell viability in a dose-dependent manner and suppressed proliferation with a stronger apoptotic activity than TSA and SAHA. SNUCH-1 inhibited HDAC enzyme activity and blocked cell cycle progression at G2/M, regulating cell cycle related protein expression more effectively than TSA and SAHA. In addition, SNUCH-1 significantly reduced tumor volume and revealed more powerful anti-tumor effect in vivo than TSA. Our results suggest that the novel HDAC inhibitor, SNUCH-1, is a potent therapeutic candidate for glioblastoma. Key words: Histone deacetylase inhibitor, glioblastoma, intracisternal administration Citation Format: Seung Ah Choi, Phi Ae Kwak, Young Eun Lee, Ji Hoon Phi, Jung Won Choi, Kyu-Chang Wang, Chul-Kee Park, Seung-Ki Kim. Anticancer effects of a novel histone deacetylase inhibitor, SNUCH-1, in glioblastoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5385. doi:10.1158/1538-7445.AM2015-5385